Advertisment

Pfizer Halts Trials of Twice-Daily Obesity Drug Due to Significant Side Effects

author-image
Justice Nwafor
New Update
Pfizer Halts Trials of Twice-Daily Obesity Drug Due to Significant Side Effects

Pharmaceutical powerhouse, Pfizer, has halted its trials on a twice-daily formulation of an obesity drug named danuglipron, citing significant side effects experienced during its Phase 2b clinical trial. The decision follows high rates of adverse reactions, leading to over half of the trial participants discontinuing the medication. The side effects were primarily gastrointestinal, including nausea, vomiting, and diarrhea.

Advertisment

Meeting Primary Objectives Amid Challenges

Despite these hurdles, the drug achieved its primary aim of statistically significant weight reduction from the baseline in the study. Pfizer remains optimistic, intending to shift its focus towards developing a once-daily formulation of danuglipron, in the hopes of enhancing its tolerability, and streamlining the study design and execution for future trials.

A History of Setbacks

This isn't the first time Pfizer has faced a setback in its quest to break into the lucrative obesity market. Earlier in June, the company discontinued another obesity drug, lotiglipron, due to concerns over potential liver damage. These concerns arose after increased levels of the enzyme transaminase were detected in its Phase 1 and Phase 2 studies.

The announcement of the cessation of trials for the twice-daily formulation of danuglipron resulted in a significant drop in Pfizer's stock value. The company's shares dropped over 4% in early trading following the announcement.

Advertisment
Advertisment